scholarly journals Chloroquine diphosphate suppresses liver cancer via inducing apoptosis in Wistar rats using interventional therapy

2021 ◽  
Vol 21 (3) ◽  
Author(s):  
Xiaoguang Hao ◽  
Weijing Li
Keyword(s):  
Liver Cancer ◽  
Wistar Rats ◽  
Interventional Therapy ◽  
Chloroquine Diphosphate

scholarly journals Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Ying Jia ◽  
Yufei Xing ◽  
Meitian Yang
Keyword(s):  
Survival Rate ◽  
Liver Cancer ◽  
Remission Rate ◽  
Primary Liver Cancer ◽  
Interventional Therapy ◽  
Skin Reactions ◽  
Group A ◽  
And Migration ◽  
One Year ◽  
Group B

Objective. To explore the efficacy of sorafenib combined with interventional therapy on primary liver cancer (PLC) patients and its effect on serum AFP, VEGF, and GGT. Methods. 120 PLC patients admitted to our hospital from January 2019 to January 2020 were selected as the research object and divided into group A and group B according to the admission order, with 60 cases each. Interventional therapy was performed to both groups, and sorafenib was given to group A additionally to compare their treatment effect, survival, adverse reaction rate (ARR), and serum AFP, VEGF, and GGT levels. Results. After treatment, group A obtained significantly higher objective remission rate (ORR) and disease control rate (DCR) ( p < 0.05 ), higher one-year survival rate and two-year survival rate ( p < 0.05 ), lower ARR of skin reactions, gastrointestinal reactions, hepatorenal reactions, and hyperbilirubinemia ( p < 0.05 ), and lower serum AFP, VEGF, and GGT levels ( p < 0.001 ). Conclusion. The combination of sorafenib and interventional therapy can inhibit the growth and migration of PLC, improve the immune function, prolong the survival period of patients, and lower ARR, so it should be promoted in practice.

The protective role of etoricoxib against diethylnitrosamine/2-acetylaminofluorene-induced hepatocarcinogenesis in Wistar rats: The impact of NF-κB/COX-2/PGE2 signaling

2021 ◽  
Vol 14 ◽  
Author(s):  
Gaber F. Ali ◽  
Hany A. Omar ◽  
Fatema Hersi ◽  
Amira M. Abo-Youssef ◽  
Osama M. Ahmed ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Wistar Rats ◽  
Nuclear Factor Kappa B ◽  
Interleukin 1 ◽  
Lipid Peroxide ◽  
Nuclear Factor ◽  
Nonalcoholic Fatty Liver ◽  
Nuclear Factor Kappa ◽  
Cox 2 ◽  
The Impact

Background: Liver cancer ranks as the 7th and 5th leading cause of cancer morbidity worldwide in men and women, respectively. Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is associated with an increasing global burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Objective: The present study aimed to investigate the possible chemopreventive effect of etoricoxib on diethylnitrosamine (DENA) and 2-acetylaminofluorene (2AAF)-induced HCC in male Wistar rats. Methods: HCC was induced by DENA (150 mg/kg/week; i.p) for 2 weeks, then 2AAF (20 mg/kg; p.o) every other day for three successive weeks. Etoricoxib (0.6 mg/kg, p.o.) was given to DENA/2AAF-administered rats for 20 weeks. Results: Etoricoxib significantly suppressed alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19.9) as liver tumor biomarkers. It also decreased serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin levels while increasing serum albumin levels. Besides, it alleviated DENA/2AAF-induced histopathological abrasions and inflammatory cell infiltration. Furthermore, etoricoxib showed a potent antioxidant effect, supported by a significant lipid peroxide reduction and elevation in superoxide dismutase and GSH content activity. In addition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta (IL-1β), tumor necrosis factor α (TNFα), nuclear Factor-kappa B (NF-κB), phosphorylated nuclear Factor-kappa B (p-NF-κB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2). Conclusion: In conclusion, the current results proved that etoricoxib possesses an anticarcinogenic effect via its antioxidant, anti-inflammatory, and modulation of NF-κB/COX-2/PGE2 signaling.

scholarly journals Role of wild type p53 and double suicide genes in interventional therapy of liver cancer in rabbits

2012 ◽  
Vol 27 (8) ◽  
pp. 522-528 ◽  
Author(s):  
Hong-xin Niu ◽  
Tong Du ◽  
Zhong-fa Xu ◽  
Xi-kun Zhang ◽  
Ruo-gu Wang
Keyword(s):  
Gene Therapy ◽  
Liver Cancer ◽  
P53 Gene ◽  
Interventional Therapy ◽  
Inhibitory Effect ◽  
Cancer Growth ◽  
Tumor Growth Rate ◽  
Significant Difference ◽  
Group 5 ◽  
Group 2

PURPOSE: To investigate the feasibility of interventional lipiodol embolism and multigene therapy in combination with focal chemotherapy in the treatment of VX2 liver cancer in rabbits. METHODS: Forty five rabbits with cancer larger than 2cm in diameter were randomly divided into five groups (n=9 per group). In Group 1, animals were treated with 0.9% sodium chloride. In Group 2, animals received lipiodol embolism. In Group 3, animals received lipiodol embolism and p53 gene therapy. In Group 4, animals received lipiodol embolism and TK/CD gene therapy. In Group 5, animals received lipiodol embolism and p53 and TK/CD gene therapy. Ultrasonography and CT were performed before and at ten days after interventional therapy. RESULTS: The VX2 model of liver cancer was successfully established in rabbits and interventional therapy smoothly performed. At ten days after interventional therapy, significant difference in the tumor volume was noted among five groups (p<0.05) and different treatments could inhibit the cancer growth. The inhibition of cancer growth was the most evident in the Group 5. Factorial analysis revealed gene therapy with p53 or TK/CD and lipiodol embolism independently exert significantly inhibitory effect on cancer growth. In addition, the suppression on tumor growth rate was the most obvious in the Group 5. CONCLUSIONS: Combination of gene therapy with lipiodol embolism can effectively inhibit the cancer growth and prolong the survival time. These findings demonstrate the effectiveness of multigene therapy in combination with lipiodol embolism in the treatment of liver cancer.

A novel sub-staging system for prognosis prediction of Barcelona clinic liver cancer C stage hepatocellular carcinoma: 10 years observational study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16139-e16139
Author(s):  
Zhiqiang Mo ◽  
Qicong Mai ◽  
Jian He ◽  
Xiaoming Chen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Staging System ◽  
Predictive Performance ◽  
Interventional Therapy ◽  
Tumor Burden ◽  
Barcelona Clinic Liver Cancer ◽  
Related Factors ◽  
Linear Predictor ◽  
Individual Survival

e16139 Background: This study sought to propose a novel sub-staging system which could predict prognosis of patients with Barcelona clinic liver cancer (BCLC) C stage Hepatocellular carcinoma (HCC). Methods: Between January 2008 and September 2018, 806 patients with BCLC-C stage HCC were assessed retrospectively. The significance of clinical variables in predicting prognosis were statistical analysis. A prognostic sub-staging system of BCLC-C stage HCC was developed according to prognosis-related factors. The predictive performance was subsequently validated. Results: In training set, tumor burden (TB) >50%, type III/IV portal vein tumor thrombus (PVTT), extrahepatic metastasis (M) and Child-Pugh (CP) B class were independently associated with overall survival (OS). According to those prognosis-related factors, a novel sub-staging system of BCLC-C stage was “linear predictor= TB+PVTT+M+CP”, which had good performance in predicting OS in both training and validation set. The thirtieth percentile and the third quartile of the linear predictor, namely 6 and 12, were selected as cut-off values, stratifying patients into different OS after interventional therapy (IT) or sorafenib therapy (ST), specifically, ≤6: 43.7 months for IT, 32.0 month for ST;＞6 but＜12: 43.7 months for IT, 32.0 month for ST; ≥12: 43.7 months for IT, 32.0 month for ST. Conclusions: The novel sub-staging system of BCLC-C stage HCC may stratify patients for suitable therapy and predict individual survival with favorable performance and discrimination.

scholarly journals Long-Term Radioiodine Retention and Regression of Liver Cancer after Sodium Iodide Symporter Gene Transfer in Wistar Rats

2004 ◽  
Vol 64 (21) ◽  
pp. 8045-8051 ◽  
Author(s):  
Jamila Faivre ◽  
Jérôme Clerc ◽  
René Gérolami ◽  
Julie Hervé ◽  
Michèle Longuet ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Liver Cancer ◽  
Wistar Rats ◽  
Sodium Iodide ◽  
Sodium Iodide Symporter

scholarly journals Effect of Radiofrequency Ablation with Interventional Therapy of Hepatic Artery on the Recurrence of Primary Liver Cancer and the Analysis of Influencing Factors

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Sishuo Zhang ◽  
Ge Zhao ◽  
Honglin Dong
Keyword(s):  
Radiofrequency Ablation ◽  
Treatment Group ◽  
Liver Cancer ◽  
Hepatic Artery ◽  
Primary Liver Cancer ◽  
Combined Treatment ◽  
Interventional Therapy ◽  
Control Group ◽  
Tumor Diameter ◽  
Significant Difference

Background. The probability of liver cancer recurring in patients after surgery is a serious threat to liver cancer patients. Radiofrequency ablation is widely employed in liver cancer cases. We explored the therapeutic effects and influencing factors of radiofrequency ablation combined with hepatic artery intervention in patients with recurrence of primary liver cancer surgery. Methods. 90 patients with primary liver cancer postoperative recurrence admitted to our hospital from January 2014 to February 2017 were selected as the research objects. The patients were randomly divided into the control group (n = 45) and combined treatment group (n = 45). The combined treatment group received radiofrequency ablation combined with hepatic artery interventional therapy, and the control group received hepatic artery interventional therapy. The short-term efficacy, AFP levels before and after treatment, and long-term survival results of the two groups were compared. Single-factor and multifactor analyses of the clinical information of the combined treatment group were carried out to find out the factors affecting the therapeutic effect of radiofrequency ablation combined with hepatic artery intervention on patients with recurrence of primary liver cancer. Results. The total effective rate of short-term curative effect of the combined treatment group was higher than the control group, and there was a statistically significant difference existing ( P  < 0.05). After treatment, two groups of patients’ AFP levels were greatly lower than before treatment, the AFP levels of the combined treatment group were significantly lower than the control group, and there was a statistically significant difference ( P  < 0.05). The survival rates of patients in the combined treatment group at the sixth month, the first year, and the second year after treatment were significantly higher than those of the control group, and there was a statistically significant difference ( P  < 0.05). The univariate results showed that, in the combined treatment group, there were statistically significant differences between the effective group and the ineffective group in tumor diameter, intact capsule, liver cirrhosis, intrahepatic spread, and tumor adjacent to large blood vessels ( P  < 0.05). The outcomes of multivariate analysis indicated that tumor diameter ≥ 3 cm, incomplete capsule, intrahepatic spread, and tumor adjacent to large blood vessels were risk factors for ineffective recurrence of patients with primary liver cancer after radiofrequency ablation combined with hepatic artery intervention ( P  < 0.05). Discussion. Tumor diameter ≥ 3 cm, incomplete capsule, intrahepatic spread, and tumor adjacent to large blood vessels are risk factors for the ineffectiveness of radiofrequency ablation combined with hepatic artery interventional therapy for patients with recurrence of primary liver cancer. It is necessary to increase the range of radiofrequency treatment, increase the temperature of the radiofrequency needle, and strengthen postoperative follow-up interventions based on the specific conditions of the patient's tumor.

scholarly journals Analysis on Effects of Comprehensive Nursing Care Applied in Interventional Therapy for Patients with Liver Cirrhosis and Liver Cancer

2019 ◽  
Author(s):  
Yuli GOU ◽  
Jing YI ◽  
Mei JIANG ◽  
Chunhong CAO
Keyword(s):  
Liver Cirrhosis ◽  
Postoperative Complications ◽  
Liver Cancer ◽  
Nursing Care ◽  
Survival Rates ◽  
Nursing Intervention ◽  
Interventional Therapy ◽  
Control Group ◽  
Observation Group

Background: This study aimed to investigate the effects of comprehensive nursing intervention in interventional therapy for patients with liver cirrhosis and liver cancer. Methods: Overall, 512 liver cirrhosis patients complicated with liver cancer receiving interventional therapy in the Department of Oncology of the Second Hospital of Dalian Medical University (Dalian, China) from March 2010 to March 2016 were retrospectively analyzed. Patients were divided into observation group (n=310) and control group (n=202). Comprehensive nursing intervention was applied to observation group and conventional nursing care was applied to control group. Results: The degrees of satisfaction before and after nursing intervention, quality-of-life scores, incidences of postoperative complications and survival rates at 20 months after operation of the two groups were compared. The degree of great satisfaction in observation group was significantly higher than that in control group (P<0.001). The quality-of-life scores of the patients in observation group were obviously higher than those in control group (P<0.001). The incidence of postoperative complications in observation group was significantly lower than that in control group (P<0.001). The survival rates in observation group was significantly higher than that in control group (P=0.035). Conclusion: The application of comprehensive nursing intervention in the interventional therapy for liver cirrhosis and liver cancer can notably improve the life quality of the patients, lower the incidence of postoperative complications and increase the survival rate, which is worthy of clinical popularization and application.

Sign in / Sign up

Export Citation Format

Share Document